Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GRK6 | P43250 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 3/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028276 | 0.84 | HRH1 (0.57) | TAAR1PIN1KDM4EMGAMGAA | |
| SCHEMBL15974857 | 0.84 | HRH1 (0.57) | TAAR1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL3012997 | 0.83 | HRH1 (0.60) | TAAR1PIN1KDM4EMEN1KMT2A | |
| SCHEMBL28128066 | 0.83 | MAOB (0.44) | TAAR1KDM4EKMT2AHTR2AIDO1 | |
| SCHEMBL5035220 | 0.82 | KMO (0.40) | TAAR1MAPTKMT2AHTR2AMGAM | |
| SCHEMBL1436268 | 0.82 | LOXL2 (0.40) | TAAR1PIN1KDM4EMEN1MAPT | |
| SCHEMBL30902079 | 0.75 | IDO1 (0.51) | PIN1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL29212573 | 0.75 | IDO1 (0.51) | PIN1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL28128068 | 0.75 | DCUN1D1 (0.42) | TAAR1HTR2AMGAMGAASI | |
| SCHEMBL15348460 | 0.74 | HPGDS (0.51) | PIN1KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053831-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | DIAMOND THERAPEUTICS INC (CA) | 2026-02-26 | — | — | US | disclosed |
| US-20260053829-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | DIAMOND THERAPEUTICS INC (CA) | 2026-02-26 | — | — | US | disclosed |
| US-11628144-B2 | Iniparib formulations and uses thereof | TRIACT THERAPEUTICS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| CN-114306613-A | Pharmaceutical composition | 查尔斯顿实验室公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220096504-A1 | METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVORIAL, AND/OR MOOD DISORDERS | DIAMOND THERAPEUTICS INC. (CA) | 2022-03-31 | — | — | US | disclosed |
| US-20220062276-A1 | PHARMACEUTICAL COMPOSITIONS | LOCL PHARMA, INC. (US) | 2022-03-03 | — | — | US | disclosed |
| CN-114040767-A | Methods and compositions comprising 5HT receptor agonists for the treatment of psychological, cognitive, behavioral and/or emotional disorders | 钻石治疗公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3917537-A1 | METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVIORAL, AND/OR MOOD DISORDERS | Diamond Therapeutics Inc. (CA) | 2021-12-08 | — | — | EP | disclosed |
| US-20210145756-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20200297644-A1 | INIPARIB FORMULATIONS AND USES THEREOF | TRIACT THERAPEUTICS, INC. | 2020-09-24 | — | — | US | disclosed |
| WO-2010017264-A2 | PHOTO-CROSSLINKED NUCLEIC ACID HYDROGELS | CORNELL UNIVERSITY (US) | 2010-02-11 | — | — | WO | disclosed |
| EP-2124556-A2 | PHARMACEUTICAL COMPOSITIONS | Charleston Laboratories, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009089494-A2 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090175939-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080280955-A1 | Methods and compositions for screening and treatment of disorders of blood glucose regulation | PERLEGEN SCIENCES, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1931805-A2 | METHODS AND COMPOSITIONS FOR SCREENING AND TREATMENT OF DISORDERS OF BLOOD GLUCOSE REGULATION | Perlegen Sciences, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008070268-A2 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20070148246-A1 | Nucleic Acid-Based Matrixes | CORNELL RESEARCH FOUNDATION INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070117177-A1 | Nucleic Acid-Based Matrixes for Protein Production | CORNELL RESEARCH FOUNDATION, INC. | 2007-05-24 | — | — | US | disclosed |
| WO-2007038670-A2 | METHODS AND COMPOSITIONS FOR SCREENING AND TREATMENT OF DISORDERS OF BLOOD GLUCOSE REGULATION | PERLEGEN SCIENCES, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053829-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | HTR1A, HTR5A, HTR3B | TAAR1 36/4885PIN1 4362/4885KDM4E 4697/4885 |
| US-20200297644-A1 | INIPARIB FORMULATIONS AND USES THEREOF | INPP5B, INPPL1, PARP3 | TAAR1 3562/4885PIN1 1630/4885KDM4E 3120/4885 |
| US-20220096504-A1 | METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVORIAL, AND/OR MOOD DISORDERS | HTR1A, HTR2B, HTR7 | TAAR1 22/4885PIN1 4409/4885KDM4E 1101/4885 |
| US-11628144-B2 | Iniparib formulations and uses thereof | INPP5B, INPPL1, PARP3 | TAAR1 3562/4885PIN1 1630/4885KDM4E 3120/4885 |
| US-20260053831-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | HTR1B, HTR2B, HTR3B | TAAR1 92/4885PIN1 4070/4885KDM4E 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.